Catheterization Labs Market Size, Share, and Growth Forecast 2026 - 2033

The global catheterization labs market size is likely to be valued at US$12.4 billion in 2026 and is estimated to reach US$19.7 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033, driven by the rising burden of coronary and structural heart disease and the steady shift toward image-guided, minimally invasive cardiac procedures. Hospitals are also modernizing traditional suites with low-dose imaging and integrated physiology tools.

Driver - Rising Cardiovascular Disease Burden to Propel Procedure Volumes

Cardiovascular disease remains the main reason hospitals build, expand, and upgrade catheterization labs. The American Heart Association's 2026 statistics update reported that coronary heart disease was the underlying cause of 349,470 U.S. deaths in 2023, while about 125.9 million adults, or 47.3%, had high blood pressure in 2021 to 2023, and compared with 46.7% in the previous period.

Although total U.S. cardiovascular deaths declined to 915,973 in 2023 from 941,652 in 2022, the population living with risk factors and established disease continues to expand. This sustains demand for diagnostic angiography and revascularization, and encourages hospitals to keep lab capacity available around the clock for emergency heart attack care.

Outpatient Reimbursement Shift to Bolster Ambulatory Cath Lab Investment

Payment policy is beginning to move selected cardiac procedures out of hospital outpatient departments. In its 2026 hospital outpatient and ambulatory surgical center (ASC) final rule, published on November 21, 2025, the Centers for Medicare & Medicaid Services (CMS) added cardiac catheter ablation codes to the ASC covered procedures list, effective January 1, 2026. Medicare had historically allowed these ablations only in hospital outpatient departments.

This creates new demand for compact, electrophysiology-capable procedure rooms with integrated imaging, mapping, and recording systems outside large hospitals, giving equipment suppliers a channel for small, workflow-efficient configurations.

Restraint - Radiation Exposure and Workforce Constraints May Slow Lab Expansion

Occupational radiation exposure remains a serious concern for interventional teams. In a survey described by the Society for Cardiovascular Angiography and Interventions (SCAI), 50% of members reported orthopedic problems, one-third reported serious cervical spine issues, and 5% reported cancer. Reducing these risks requires investment in low-dose imaging, shielding, and dose-monitoring tools, which raises lab costs.

Staffing is a second constraint. SCAI has pointed to continuing physician and staffing shortages, and CMS finalized only a 2.6% increase in hospital outpatient payment rates for 2026, which offers limited relief against inflation and workforce costs. These pressures can delay lab openings and extend equipment replacement cycles.

Opportunity - Integrated Imaging and Physiology Tools to Improve Procedural Precision

Complex percutaneous coronary interventions increasingly require more than angiography alone. Intravascular imaging and physiological assessment help clinicians judge lesion severity, select stent size, and confirm results. Suppliers that embed these functions within the angiography platform can shorten decision time and increase the value of each lab installation.

Philips' IntraSight Plus is a key example. Introduced in March 2026 alongside its Azurion suites, it brings physiology, imaging, and decision support into one workflow. The first patient case was performed on March 19, 2026, at Cellitinnen-Krankenhaus St. Vinzenz in Cologne, Germany, for a patient with ST-elevation myocardial infarction and complex three-vessel disease, who received complete revascularization before discharge.

Robotic Navigation to Strengthen Operator Safety and Procedural Precision

Robotic-assisted percutaneous coronary intervention is emerging as a way to address the limitations of manual procedures while reducing operator exposure to radiation. A peer-reviewed review on cath lab radiation protection noted that the CorPath GRX system received FDA approval in 2017 and gained widespread adoption across U.S. facilities.

Recent activity reflects this direction. On July 9, 2026, Stereotaxis announced that it had completed its acquisition of Robocath, after receiving FDA 510(k) clearance for its Synchrony system on April 6, 2026. Consolidation may help suppliers offer more complete navigation and guidance capabilities.

Product Type Insights

Angiography systems are predicted to lead with a share of about 41.6% in 2026, as the imaging platform is the central and most capital-intensive asset in a catheterization lab, and every diagnostic and interventional procedure depends on it. Purchase decisions are shaped by image quality, radiation dose, and compatibility with physiology, mapping, and structural heart tools, with low-dose imaging based on the ALARA (as low as reasonably achievable) principle now a key criterion.

Hemodynamic monitoring systems are estimated to be the fastest-growing segment over the forecast period, as pressure recording, physiologic assessment, and signal analysis have become routine parts of complex coronary, electrophysiology, and structural heart cases. Demand is also supported by the shift toward integrated recording hubs and software that combine several data streams into a single view.

Application Insights

Coronary artery disease is anticipated to dominate with a share of around 46.3% in 2026, as diagnostic angiography and percutaneous coronary intervention remain the highest-volume procedures across most labs. The segment is supported by round-the-clock emergency pathways, as timely coronary intervention is the standard treatment for ST-elevation myocardial infarction.

Electrophysiology is expected to be the fastest-growing application over the forecast period, as catheter ablation for atrial fibrillation is moving toward outpatient care and pulsed field ablation technologies are gaining clinical attention. The addition of ablation codes to the ASC covered procedures list from January 2026 is expected to widen the range of settings where these procedures are performed.

North America Catheterization Labs Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 39.4%, due to a dense base of hospital cardiac programs, established reimbursement pathways, and early adoption of new imaging and navigation technologies. The American Heart Association reported that heart disease and stroke claimed more U.S. lives in 2023 than all forms of cancer and chronic lower respiratory disease combined. This keeps procedure demand steady and makes replacement of aging angiography systems a recurring priority.

U.S. Catheterization Labs Market Trends

A share of nearly 85.8% is expected to be held by the U.S. in 2026 in North America, as it has a large population with cardiovascular disease and a highly developed network of interventional cardiology programs. Between 2021 and 2023, 130.6 million U.S. adults, or 48.9%, had some form of cardiovascular disease, and total direct and indirect costs reached $414.7 billion in 2021 to 2022. This burden is encouraging hospitals and outpatient operators to modernize their labs.

Asia Pacific Catheterization Labs Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 24.6%, as governments and private hospital groups are expanding cardiac care networks while the burden of coronary disease keeps rising. Large populations, growing insurance coverage, and investment in tertiary care centers are creating demand for new labs, particularly in China and India.

China Catheterization Labs Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 34.1%, supported by a nationwide effort to standardize emergency chest pain care. A peer-reviewed program overview reported that 4,621 hospitals had registered with the National Chest Pain Centers Program as of September 2020, of which 1,507 were accredited. The Chinese Society of Cardiology also updated its national PCI guideline in 2025, focusing on operator training and quality supervision.

India Catheterization Labs Market Trends

In 2026, India is projected to account for a share of just about 11.8% in Asia Pacific, as access to catheterization facilities is still limited outside major urban centers, leaving substantial room for expansion. A 2024 facility mapping study in the Indian Journal of Medical Research found that, in the district examined, only the district hospital offered angiography, angioplasty, and coronary care beds, and even those services were outsourced to a private provider. Hub-and-spoke heart attack programs, such as the ICMR-supported Tamil Nadu model, are strengthening the case for labs at regional referral hospitals.

Europe Catheterization Labs Market Trends

Europe will likely see steady growth over the forecast period with a share of roughly 25.7% in 2026 globally, as it has a mature network of interventional cardiology centers and a strong tradition of guideline-based care. The European Society of Cardiology's 2025 statistics report, released in May 2026, found that cardiovascular disease causes more than 3 million deaths per year across its member countries. The European Union also adopted its Safe Hearts Plan in December 2025, which may strengthen policy attention on cardiovascular services.

Germany Catheterization Labs Market Trends

Germany is predicted to register a substantial share of approximately 22.5% in 2026 in Europe, as it has one of the region's densest cardiac catheterization infrastructures. Data from the German Heart Report 2018 cited by the German Cardiac Society show that more than 1,000 left heart catheterization measuring stations performed about 880,000 procedures in 2017, and roughly 42.9% of these included a percutaneous coronary intervention. This large base supports steady replacement demand for imaging systems.

U.K. Catheterization Labs Market Trends

A share of nearly 15.4% is predicted to be held by the U.K. in 2026 in Europe, due to a well-organized national audit system and rising use of advanced techniques. The National Audit of Percutaneous Coronary Interventions, led by the British Cardiovascular Intervention Society and managed by NICOR, reported a further increase in intracoronary imaging for complex PCI in its 2026 update, alongside slight improvements in treatment times for heart attack patients. The NICOR annual report has also highlighted post-pandemic capacity recovery and staff retention as continuing challenges for cardiac services.

The global catheterization labs market is moderately consolidated and highly competitive, with imaging-system manufacturers, monitoring and contrast-management specialists, and accessory suppliers competing through image quality, dose reduction, integration of physiology and imaging tools, software capabilities, and service coverage. Koninklijke Philips, Siemens Healthineers, GE HealthCare, Canon Medical Systems, and Shimadzu have established positions in angiography platforms, while specialty companies are strengthening positions in robotics, MR-guided procedures, and guidance software.

Key Industry Developments

• In June 2026, GE HealthCare introduced upgrade pathways for selected Innova, Discovery, and Allia interventional systems. The pathways allow healthcare providers to add newer Allia technologies and workflows while retaining portions of their existing infrastructure. GE HealthCare said the approach is intended to reduce the need for major construction, extend the useful life of interventional rooms, and minimize disruption to clinical operations
• In May 2026, Siemens Healthineers introduced an integrated end-to-end CT-guided PCI workflow combining Syngo.CT Coronary Cockpit, Syngo.via, Syngo PCI Connect, and its Artis angiography systems. The solution transfers pre-processed CT information into the cath lab, including coronary anatomy, plaque information, lumen dimensions, and planned stent positions. The system also synchronizes CT images with C-arm movement, allowing physicians to use pre-procedural CT information during the intervention.
• In March 2026, an international randomized trial presented at the American College of Cardiology's Scientific Session evaluated CathWorks' FFRangio software-based coronary physiology assessment. The study found that the software-based approach produced similar one-year clinical outcomes to invasive wire-based fractional flow reserve assessment. The findings provide additional clinical evidence for angiography-derived physiological assessment as an alternative workflow within the cath lab.